How Medical Device Companies Are Valued
Medical device M&A is one of the widest valuation ranges in healthcare. Two companies with identical revenue can trade at multiples 4-5x apart depending on FDA classification, reimbursement status, IP defensibility, and the strategic rationale of the buyer. Treating "medical devices" as a single category is the fastest way to misprice a deal.
FDA Classification Drives the Multiple Range
Class II 510(k) cleared devices , the bulk of the device market, typically trade at a revenue-multiple range or platform-tier earnings multiples depending on growth, channel, and IP. Established commodity-adjacent devices (basic surgical instruments, standard imaging accessories, disposables) sit at the lower end. Differentiated 510(k) devices with reimbursement codes and a defensible sales channel push to the upper end.
Class III implants and specialty devices , PMA-approved cardiovascular, neuromodulation, structural heart, spine, and ortho implants, command a revenue-multiple range. The premium reflects the regulatory moat (PMA approval is a multi-year capital expense competitors can't skip), longer product life cycles, and higher per-unit ASPs. Stryker's spine and ortho roll-ups, Edwards' structural heart program, and Boston Scientific's electrophysiology bolt-ons consistently price in this band.
Diagnostic equipment and IVD typically trades at a revenue-multiple range, with consumable/razor-blade business models pulling the multiple up materially. A diagnostic instrument company where 60%+ of revenue is recurring assay/reagent sales is valued more like a SaaS business than capital equipment.
Software as a Medical Device (SaMD) is the highest-multiple device category in the market. AI-enabled diagnostic software, surgical planning platforms, and connected device software trade at a revenue-multiple range when growth is >30% and gross margins exceed 75%. The sub-segment is small but pricing reflects pure-software economics applied to a regulated market.
What Public Comps Tell Us
The strategic acquirer landscape is dominated by a handful of large-cap public companies whose own trading multiples set the ceiling. Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Intuitive Surgical, ResMed, and Abbott's medical device segment collectively define the public-comp anchor at roughly platform-tier earnings multiples at the corporate level. Stryker and Boston Scientific are particularly active acquirers and consistently pay above their own trading multiple for tuck-ins that fit existing call points.
Strategic premium matters enormously. A $30M revenue spine implant company sold standalone might price at platform-tier earnings multiples. The same company sold to Stryker, where the product can be pushed through an existing 1,000-rep sales force and immediately layered into surgeon relationships, frequently prices at platform-tier earnings multiples. Strategic synergies are real and captured in the multiple.
SMB Medical Device Companies (the $5-50M Revenue Range)
Most founder-owned medical device companies I see fall in the $5-50M revenue range with $1-10M EBITDA. The valuation range for this cohort is platform-tier earnings multiples with the spread driven almost entirely by four factors:
FDA approval status. 510(k) cleared with active CPT or HCPCS reimbursement codes is the entry-level moat. Pre-submission or De Novo pathway adds significant valuation risk and pulls the multiple to the bottom of the range. PMA approval, even for a single indication, moves the company to a different valuation tier entirely.
IP defensibility. Issued utility patents covering the device mechanism of action, blocking design-around competitors, materially impact what a strategic will pay. Patent expirations within 5 years of close are a common deal-breaker on premium pricing.
Sales channel. Direct sales force selling into a known call point (cath lab, OR, GI suite) is worth more than independent distributor channels because it's harder for a strategic acquirer to replicate. Companies selling through 1099 reps with no direct rep relationships consistently price 2-3 turns lower.
Reimbursement clarity. Devices paid under existing CPT codes with published Medicare rates trade at a premium over devices that require physicians to seek unlisted code reimbursement. A favorable Category I CPT code is, in practice, a multi-turn multiple add.
What Decreases Medical Device Company Value
Single-product concentration is the most common multiple compressor. Companies where 80%+ of revenue is one device with one indication carry concentration risk that strategics price in. A pipeline of follow-on products at varying maturity stages commands a premium.
Open FDA correspondence , 483 observations, warning letters, recalls, or pending pre-market submissions in question status, meaningfully impacts pricing and can derail a deal entirely if not disclosed early. Strategic acquirers almost always require quality-system due diligence well before LOI.
Customer concentration in GPO contracts where a single contract represents >a percent-of-revenue figure creates renewal risk that strategics will model conservatively. The same is true for IDN-heavy customer mixes where 3-4 health systems drive most of the volume.